Strategies for Managing AEs and Promoting Adherence to CDK4/6 Inhibitors

In this on-demand webcast, an expert discusses strategies for managing adverse events related to CDK4/6 inhibitor use in the treatment of early-stage and advanced breast cancers and promoting medication adherence.

• Apply recommended strategies to improve patient recognition of adverse events associated with CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer and to monitor and manage the AEs appropriately

• Initiate discussions with patients to identify and address challenges to adherence and persistence with oral therapies targeting CDK4/6

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours, including 0.5 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education 

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until August 10, 2025. PAs should only claim credit commensurate with the extent of their participation. 

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Nicolle Rochino, PharmD, RPh: employee (relationship has ended): Novo Nordisk.​